Analytical Comparability to Evaluate Impact of Manufacturing Changes of ARX788, an Anti-HER2 ADC in Late-Stage Clinical Development https://www.biorxiv.org/content/10.1101/2023.03.27.534450v1?med=mas
CleverLibre Social is an inclusive social instance for open discussion, learning, and community. All cultures welcome. Hate speech and harassment strictly forbidden.